2002052595

30 AUG 2002

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
7 September 2001 (07.09.2001)

PCT

(10) International Publication Number
WO 01/64739 A1

(51) International Patent Classification[7]: C07K 14/47, C12N 15/12, 9/02, 15/53, 15/66, A61K 31/70, 48/00, A61P 35/00

(21) International Application Number: PCT/GB01/00856

(22) International Filing Date: 1 March 2001 (01.03.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0005099.7	2 March 2000 (02.03.2000)	GB
60/187,465	6 March 2000 (06.03.2000)	US

(71) Applicant: COBRA THERAPEUTICS LIMITED [GB/GB]; Stephenson Building, The Science Park, University of Keele, Staffordshire ST5 5SP (GB).

(72) Inventors: YOUNG, Lawrence, Sterling; CRC Institute for Cancer Studies, Vincent Drive, Edgbaston, Birmingham B12 2TA (GB). LIPINSKI, Kai, Stefan; Cobra Therapeutics Limited, Stephenson Building, The Science Park, University of Keele, Staffordshire ST5 5SP (GB). WRIGHTON, Christopher, John; Cobra Therapeutics Limited, Stephenson Building, The Science Park, University of Keele, Staffordshire ST5 5SP (GB).

(74) Agents: JONES, Keith, William; Harrison Goddard Foote, Orlando House, 11c Compstall Road, Marple Bridge, Stockport SK6 5HH et al. (GB).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

162162

ACTION

WO 01/64739 A1

(54) Title: TCF RESPONSIVE ELEMENT

(57) Abstract: Disclosed are DNA elements and constructs useful for obtaining tumour-selective gene expression in tumours having a mutated β-catenin/APC pathway. In particular, the use of these constructs to express genes encoding therapeutic proteins in colorectal cancer cells is described. The constructs comprise multiple repeats of a TCF-binding element operably linked to a promoter. By means of such a construct, tumour cell-specific expression of a prodrug-converting enzyme such as nitroreductase may be achieved. Coupled with systemic administration of a suitable prodrug, such as CB1954, selective killing of such tumour cells can be demonstrated.